Thursday, January 23, 2014
Publication and contact
Asymmetrical Fc engineering
to enhance antibody-dependent cellular cytotoxicity (ADCC)
Antibodies engineered to
asymmetrically interact with Fc g-receptor IIIa (CD16a;
FcgRIIIa) could enhance ADCC. ADCC is
mediated through contact of antibody Fc chains with FCGR3A on NK cells upon
binding of tumor or viral antigen. In a heterodimeric Fc library, screening
of 9,000 individual antibody clones identified heterodimeric human IgG1
antibodies containing asymmetrical Fc mutations that increased binding to
FCGR3A and ADCC activity compared with wild-type human IgG1. In multiple
mouse xenograft models of cancer, heterodimeric IgG1 variants decreased tumor
size compared with normal IgG1. Next steps include enhancing ADCC activities
of therapeutic antibodies that are based on Fc heterodimers such as
Published online Jan. 23, 2014
Patent application filed;
licensing status undisclosed
Liu, Z. et al. J. Biol.
published online Dec. 5, 2013;
Contact: Wei Yan, Amgen Inc., Seattle, Wash.
Contact: Zhi Liu, same affiliation as above
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]